Alvotech Biopharmaceuticals (ALVO): Rasio rega marang prakiraan pendapatan
The current forward P/S ratio reflects market expectations for Alvotech, whose success depends on regulatory approvals and the outcome of patent wars. 3.70 serves as the final level mark. The business faces stringent FDA oversight and significant lobbying. Meanwhile, the high-tech plant operates at maximum efficiency, steadily expanding production capacities without equipment downtime.
Rincian analitis perusahaan Alvotech Biopharmaceuticals (ALVO)
- rega saiki lan proyeksi nilai saham:
- data kapitalisasi bursa:
- indikator nilai buku ekuitas:
- rincian struktur utang lan likuiditas bisnis:
Rasio Total Utang marang Ekuitas Alvotech|ALVO - Rasio silihan jangka dawa marang modal|Utang jangka cendhak marang modal Alvotech|ALVO - Utang kumulatif perusahaan|Utang-utang marang kapitalisasi buku Alvotech Biopharmaceuticals|ALVO - Kewajiban jangka dawa perusahaan|Utang jangka cendhak perusahaan Alvotech|Rasio cepet alvotech.com
- indikator pendapatan resik lan kelipatan nilai:
ALVO - Bathi resik|Bathi sing dikarepake Alvotech|ALVO - Rasio rega marang bathi|Prakiraan rega marang bathi Alvotech Corp|ALVO - Rasio rega marang bathi tumrap wutah|Nilai perusahaan marang bathi sadurunge bunga, pajeg, lan panyusutan Alvotech Biopharmaceuticals|ALVO - Bathi sadurunge bunga, pajak, lan amortisasi|Bathi saben saham sajrone rolas wulan pungkasan Alvotech|ALVO - Bathi saben siji saham sajrone 12 wulan pungkasan|Wutah bathi EPS kuartalan alvotech.com|ALVO - Tambahing bathi saben saham ing taun lumaku|Prakiraan wutah bathi kanggo taun ngarep Alvotech
- indikator pendapatan dodolan lan penghasilan bisnis:
Analisis wiwitan perusahaan:Alvotech SA ALVO
The forward P/S ratio determines the market value of a business relative to expected revenue, allowing for a real-time assessment of capitalization without waiting for quarterly reports. By analyzing the forward P/S ratio, an investor can see how Alvotech (ALVO) management's ambitions for biosimilar expansion and the disruption of monopolies are reflected in the price, which helps determine the entry point during production scaling.
Pesaing Alvotech (ALVO)
Multiplikator Forward P/S HLN (Haleon)|Multiplikator Forward P/S Kenvue Inc KVUE|VRNA - Rasio rega marang prakiraan pendapatan|MENS: Rasio rega marang prakiraan pendapatan|LGND (Ligand Pharmaceuticals) - Multiplikator forward rega marang pendapatan|AMRX (amneal.com) - Rasio rega marang prakiraan pendapatan|Rasio rega marang prakiraan pendapatan Perrigo|Rasio kapitalisasi pasar marang pendapatan mangsa ngarep Liquidia Corp LQDA|Multiplikator forward rega marang pendapatan GLPG (Galapagos Genomics)|Rasio rega marang pendapatan sing dikarepake ANIP|Multiplikator Forward P/S MNKD (MannKind Corporation)|amphastar.com (AMPH) - Rasio kapitalisasi pasar marang pendapatan mangsa ngarep|Pacira BioSciences, Inc. - Multiplikator Forward P/S|ARS Pharmaceuticals Inc (SPRY) - Multiplikator forward rega marang pendapatan|TBPH: Multiplikator Forward P/S|Aquestive Corp - Rega forward marang dodolan|SCPH (scPharmaceuticals, Inc.) - Multiplikator Forward P/S|Multiplikator Forward P/S Tectonic|Rasio rega marang prakiraan pendapatan Tonix Pharmaceuticals Holding Corp. (TNXP)|Rasio rega marang prakiraan pendapatan SXTC (sxtchina.com)|Eupraxia Pharmaceuticals Inc. - Multiplikator forward rega marang pendapatan|BioHarvest Sciences Inc - Rasio rega marang prakiraan pendapatan|EXOZ - Rasio rega marang prakiraan pendapatan|Rasio kapitalisasi pasar marang pendapatan mangsa ngarep Oramed Pharmaceuticals|enterabio.com (ENTX) - Rasio rega marang prakiraan pendapatan|Rega mangsa ngarep marang pendapatan HYFT (MindWalk Holdings, Inc.)|ABVC (ABVC BioPharma Inc) - Multiplikator Forward P/S|CPIX: Rega forward marang dodolan|Multiplikator Forward P/S QNTM|Multiplikator Forward P/S fibrogen.com (FGEN)|Rasio rega marang prakiraan pendapatan Telomir Pharmaceuticals, Inc. TELO|Rega forward marang dodolan RANI|SNYR - Rasio rega marang prakiraan pendapatan|Rallybio Corporation (RLYB) - Multiplikator forward rega marang pendapatan|LEXX: Multiplikator Forward P/S|pulmatrix.com (PULM) - Multiplikator Forward P/S|Multiplikator forward rega marang pendapatan PTHL|APM: Rega forward marang dodolan|Rasio rega marang prakiraan pendapatan Lyra Therapeutics, Inc (LYRA)|IBO - Rasio kapitalisasi pasar marang pendapatan mangsa ngarep|TNF Pharmaceuticals, Inc. - Multiplikator forward rega marang pendapatan|Rasio rega marang pendapatan sing dikarepake YCBD (cbdMD Inc.)|PainReform - Multiplikator Forward P/S|Rega forward marang dodolan CYTO (Altamira Therapeutics)|LIPO: Multiplikator Forward P/S|Rasio kapitalisasi pasar marang pendapatan mangsa ngarep OptiNose Corp (OPTN)|Rasio rega marang prakiraan pendapatan Pieris Pharmaceuticals|PROC: Rega forward marang dodolan|Multiplikator Forward P/S PTPI|Multiplikator Forward P/S Qilian International Holding Group (QLI)|Rasio rega marang prakiraan pendapatan ACELYRIN, Inc. SLRN|TFF Pharmaceuticals, Inc - Rasio rega marang prakiraan pendapatan
